Animal Gastroesophageal Reflux Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Diagnostics, Treatment, Others), By Animal Type (Companion Animals, Livestock Animals), By Route of Administration (Oral, Injectable), By Distribution Channel (Veterinary hospitals & clinics, Retail Pharmacies, E-commerce), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.56 Billion
CAGR (2026-2031)	8.85%
Fastest Growing Segment	Diagnostics
Largest Market	North America
Market Size (2031)	USD 5.92 Billion

Market Overview

The Global Animal Gastroesophageal Reflux Disease Market will grow from USD 3.56 Billion in 2025 to USD 5.92 Billion by 2031 at a 8.85% CAGR. The Global Animal Gastroesophageal Reflux Disease Market encompasses specific diagnostic modalities and pharmaceutical interventions, including proton pump inhibitors and H2 receptor antagonists, designed to manage acid reflux in companion animals. The primary drivers supporting market growth include the increasing trend of pet humanization, which has led to a greater willingness among owners to invest in advanced veterinary healthcare, and a rising prevalence of gastrointestinal disorders within aging pet populations. According to the American Pet Products Association, in 2024, total U.S. pet industry expenditures reached $152 billion, with $39.8 billion specifically allocated to veterinary care and product sales, illustrating the robust financial commitment owners are dedicating to animal wellness.

However, a significant challenge that could impede market expansion is the high cost associated with long-term veterinary management and specialized diagnostic procedures. These elevated expenses can create a barrier to entry for price-sensitive pet owners, potentially limiting the widespread adoption of comprehensive treatment plans and slowing the overall growth trajectory of the sector.

Key Market Drivers

Increasing global pet ownership and humanization trends are fundamentally reshaping the demand for specialized veterinary therapeutics, particularly for chronic conditions like gastroesophageal reflux disease. Owners increasingly view companion animals as family members, prompting immediate veterinary intervention for signs of discomfort such as regurgitation or dysphagia, rather than dismissing them. This emotional bond translates into higher adoption rates of diagnostic procedures and pharmaceutical interventions, expanding the addressable market for acid suppressants. According to UK Pet Food, March 2024, in the 'Pet Population 2024' report, approximately 17.2 million households in the United Kingdom own a pet, representing 60 percent of the population. This high penetration of ownership ensures a consistent and expanding patient base for managing long-term digestive health issues.

The rising incidence of diet-induced and obesity-related animal reflux serves as a critical clinical driver for market expansion, as excess weight significantly compromises gastrointestinal function. Obesity increases intra-abdominal pressure, leading to sphincter dysfunction and chronic acid reflux, necessitating sustained pharmacological management. However, owner recognition remains a hurdle to early treatment; according to the Association for Pet Obesity Prevention, May 2024, in the '2023 National Pet Weight and Nutrition Survey', only 17 percent of dog owners classified their pets as overweight, despite the condition's high clinical prevalence. This disparity underscores the latent market potential as diagnostic awareness improves. Furthermore, the sector's financial health supports these therapeutic advancements; according to Zoetis, in 2024, the company reported full year 2023 revenue of $8.5 billion, reflecting the robust economic capacity driving veterinary innovation.

Download Free Sample Report

Key Market Challenges

The high cost associated with long-term veterinary management and specialized diagnostic procedures constitutes a significant impediment to the growth of the Global Animal Gastroesophageal Reflux Disease Market. Diagnosing gastroesophageal reflux disease effectively often requires expensive interventions such as endoscopy or specialized pH monitoring, while treatment necessitates the chronic administration of pharmaceuticals like proton pump inhibitors. These financial demands create a substantial barrier for price-sensitive pet owners, often leading to the deferral of necessary diagnostic screenings or the discontinuation of maintenance therapies. Consequently, the market faces reduced potential revenue as distinct segments of the pet population remain undiagnosed or untreated due to economic constraints.

This economic pressure is evident in recent industry performance metrics which indicate that rising prices are affecting client behavior. According to the American Veterinary Medical Association, in 2024, data analysis from thousands of practices revealed a 2.3% decrease in patient visits compared to the prior year, a trend primarily attributed to escalating service costs forcing budget-conscious owners to limit veterinary interactions. This reduction in clinical foot traffic directly hampers the market by limiting the opportunities for veterinarians to identify and manage complex gastrointestinal conditions, thereby stalling the broader adoption of reflux disease therapeutics.

Key Market Trends

The implementation of Brachycephalic-Focused Treatment Protocols is rapidly reshaping clinical standards within the Global Animal Gastroesophageal Reflux Disease Market. Veterinary professionals are increasingly correlating Brachycephalic Obstructive Airway Syndrome (BOAS) with hiatal hernias and chronic acid reflux, necessitating specialized therapeutic regimens that combine surgical airway correction with long-term acid suppression. This breed-specific focus is driven by the sustained popularity of flat-faced dogs, which genetically require disproportionate levels of gastrointestinal care compared to other breeds. According to the American Kennel Club, March 2024, in the '2023 Most Popular Dogs in the U.S.' report, French Bulldogs retained their ranking as the most registered breed with 98,500 registrations, ensuring a continuous influx of patients requiring these targeted reflux management protocols.

Simultaneously, the Proliferation of Therapeutic Gastrointestinal Diets and Nutrition is altering the management landscape by prioritizing multimodal conservative therapy over exclusive pharmaceutical reliance. Market players are aggressively expanding portfolios of highly digestible, low-fat prescription diets and microbiome-supporting supplements designed to mitigate reflux symptoms and improve esophageal motility without the side effects of chronic drug administration. This trend reflects a broader consumer shift towards functional wellness products that serve as adjunctive therapies to standard proton pump inhibitors. According to Petfood Industry, February 2024, in the 'Purina PetCare sales hit US$21.47 billion in 2023' report, Purina Pro Plan Veterinary Supplement sales grew by 22.6% in 2023, underscoring the rapid commercial uptake of nutritional interventions for digestive health.

Segmental Insights

The Diagnostics segment is positioned as the fastest-growing area in the Global Animal Gastroesophageal Reflux Disease Market driven by the expanding utilization of endoscopy and pH monitoring systems in veterinary clinics. This rapid progression stems from a heightened focus on early detection and the preference for precise internal visualization over empirical medication. As veterinary professionals increasingly adhere to rigorous diagnostic protocols to confirm esophageal acidity and structural damage, the demand for specialized equipment has surged. This trend reflects a broader industry movement toward evidence-based practice and comprehensive animal healthcare management.

Regional Insights

North America leads the global animal gastroesophageal reflux disease market, primarily due to rising veterinary healthcare expenditure and a substantial population of companion animals. The region benefits from well-established veterinary infrastructure and increasing owner awareness regarding digestive disorders in pets. Additionally, the strong presence of key pharmaceutical companies ensures the consistent availability of therapeutic treatments. The supportive regulatory framework provided by the United States Food and Drug Administration Center for Veterinary Medicine further strengthens the market by facilitating the approval and distribution of effective medications for animal gastric health management.

Recent Developments

• In December 2025, Dechra announced the FDA approval of Emeprev (maropitant citrate) Injectable Solution, a bioequivalent antiemetic indicated for the prevention and treatment of acute vomiting in dogs and cats. The product addresses symptoms often associated with gastrointestinal disorders, including reflux and gastritis, and features a formulation containing benzyl alcohol to reduce injection pain. The President of North America for Dechra stated that the approval expanded the company's companion animal portfolio with a practical solution that meets real-world clinical needs. This launch offered veterinarians a new, effective option for managing vomiting while improving patient comfort during administration.
• In February 2025, the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency adopted a positive opinion recommending the marketing authorisation of Omeprazole TriviumVet for use in dogs. This novel veterinary medicinal product, developed as a gastro-resistant capsule, is indicated as an aid in the treatment of gastric ulceration induced by non-steroidal anti-inflammatory drugs (NSAIDs). The positive opinion was based on data demonstrating the quality, safety, and efficacy of the product, which aims to fill a therapeutic gap for canine patients requiring gastric protection. The recommendation marked a key regulatory milestone toward the product's availability across the European Union.
• In January 2025, the Dorothy Russel Havemeyer Foundation hosted a specialized meeting on Equine Gastric Ulcer Syndrome (EGUS) that was supported by Boehringer Ingelheim. The event convened researchers and veterinary experts to discuss the latest findings in gastric health, including a comprehensive review of Equine Glandular Gastric Disease (EGGD) cases analyzed over several years. The presentations highlighted critical risk factors for treatment-refractory disease and underscored the challenges in managing cases that do not respond to standard protocols. This collaboration reinforced the company's commitment to advancing the scientific understanding and management of complex gastric conditions in horses.
• In December 2024, Epicur Pharma, in partnership with the Bova Group, launched a patented injectable omeprazole formulation for the treatment of equine gastric disease in the United States. This product, which had previously been utilized in international markets, offers a prolonged duration of action that allows for administration once every five to seven days, a significant improvement over daily oral pastes. The launch provided veterinarians with an FDA-regulated alternative designed to address compliance challenges and deliver consistent acid suppression. Clinical studies supporting the formulation demonstrated improved healing rates for both squamous and glandular gastric diseases compared to traditional oral treatments.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Santé Animale S.A.
• Boehringer Ingelheim International GmbH
• McNeil Consumer Pharmaceuticals Co.
• BioZyme, Inc.
• Annamaet Petfoods Inc.
• Hill's Pet Nutrition, Inc.
• Blue Buffalo Co., Ltd.

By Product	By Animal Type	By Route of Administration	By Distribution Channel	By Region
Diagnostics Treatment Others	Companion Animals Livestock Animals	Oral Injectable	Veterinary hospitals & clinics Retail Pharmacies E-commerce	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Animal Gastroesophageal Reflux Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Animal Gastroesophageal Reflux Disease Market , By Product:

• Diagnostics
• Treatment
• Others

• Animal Gastroesophageal Reflux Disease Market , By Animal Type:

• Companion Animals
• Livestock Animals

• Animal Gastroesophageal Reflux Disease Market , By Route of Administration:

• Oral
• Injectable

• Animal Gastroesophageal Reflux Disease Market , By Distribution Channel:

• Veterinary hospitals & clinics
• Retail Pharmacies
• E-commerce

• Animal Gastroesophageal Reflux Disease Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE